Get started
Author

Sofia Sciabolacci

Observed name: S. Sciabolacci
ORCID: 0000-0002-7642-1106
Observed ORCID: 0000-0002-7642-1106
OpenAlex ID: A5033473535
Current status and future perspectives in targeted therapy of NPM1-mutated AML
2022 · Roberta Ranieri, Giulia Pianigiani, et al. · Leukemia · 137
PDF
Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field
2021 · Brunangelo Falini, Sofia Sciabolacci, et al. · Leukemia · 44
PDF
A venetoclax and azacitidine bridge‐to‐transplant strategy for NPM1‐ mutated acute myeloid leukaemia in molecular failure
2023 · C. Sartor, L. Brunetti, et al. · British Journal of Haematology · 30
HLA-haploidentical hematopoietic stem cells transplantation with regulatory and conventional T-cell adoptive immunotherapy in pediatric patients with very high-risk acute leukemia
2023 · M. S. Massei, I. Capolsini, et al. · Bone Marrow Transplantation · 9
PDF
Blinatumomab Redirects Donor Lymphocytes against CD19+ Acute Lymphoblastic Leukemia without Relevant Bystander Alloreactivity after Haploidentical Hematopoietic Stem Cell Transplantation
2023 · Antonella Mancusi, Francesco Zorutti, et al. · International Journal of Molecular Sciences · 6
PDF
The Leukemic Isocitrate Dehydrogenase (IDH) 1/2 Mutations Impair Myeloid and Erythroid Cell Differentiation of Primary Human Hematopoietic Stem and Progenitor Cells (HSPCs)
2024 · Sara Pierangeli, Serena Donnini, et al. · Cancers · 4
PDF
Venetoclax plus azacitidine as genetic-driven bridge-to-transplant therapy for IDH2-mutated acute myeloid leukaemia (AML) refractory to intensive chemotherapy: proof-of-concept case reports
2025 · Gaetano Cimino, Matteo Caridi, et al. · Annals of Hematology · 3
PDF
One disease, two faces: clonally-related AML and MPDCP with skin involvement
2023 · Giovanni Martino, Gaetano Cimino, et al. · Annals of Hematology · 3
A Chemo-Free Bridge-to-Transplant Strategy with Venetoclax and Azacitidine for NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure
2022 · Chiara Sartor, Lorenzo Brunetti, et al. · Blood · 3
CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study
2024 · Gaetano Cimino, Matteo Caridi, et al. · Blood · 2
PDF
Abstract P195: Omacetaxine mepessucinate plus venetoclax show strong synergistic anti-leukemic activity in nucleophosmin (NPM1)-mutated AML patient-derived xenograft (PDX) models to support a phase 1 clinical trial
2021 · Federica Mezzasoma, Valeria Cardinali, et al. · Molecular Cancer Therapeutics · 1
Abstract LB044: Tracking clonal hematopoiesis in patients with classical Hodgkin lymphoma
2021 · Andrea Marra, Alessandra Venanzi, et al. · Cancer Research · 1
Two Decades of NPM1-Mutated Acute Myeloid Leukemia: From Molecular Insights to Clinical Decision-Making
2026 · Gaetano Cimino, Matteo Caridi, et al. · Cancers
Durable remission despite transplantation with active disease in therapy-related NUP98::TOP1-rearranged acute myeloid leukemia
2026 · Gaetano Cimino, Rebecca Sembenico, et al. · Annals of Hematology
PDF
Prescription patterns of venetoclax in acute myeloid leukemia
2024 · Andrealuna Ucciero, Giuseppe Traversa, et al. · Hematological Oncology
Correction to: One disease, two faces: clonally-related AML and MPDCP with skin involvement
2023 · Giovanni Martino, Gaetano Cimino, et al. · Annals of Hematology
PDF
Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study
2023 · Raffaele Palmieri, Fabio Guolo, et al. · Blood
PDF
Data from Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma
2023 · Alessandra Venanzi, Andrea Marra, et al.
Supplementary Figures from Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma
2023 · Alessandra Venanzi, Andrea Marra, et al.
PDF
Supplementary Tables from Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma
2023 · Alessandra Venanzi, Andrea Marra, et al.
PDF
Supplementary Appendix from Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma
2023 · Alessandra Venanzi, Andrea Marra, et al.
P574: Cpx-351 Combined With Hematopoietic Cell Transplantation With Regulatory and Conventional T Cell Immunotherapy for High-risk Acute Myeloid Leukemia
2022 · S. Sciabolacci, L. Ruggeri, et al. · HemaSphere
Tracking Clonal Hematopoiesis in Patients With Classical Hodgkin's Lymphoma
2021 · A. Marra, A Venanzi, et al. · Hematological Oncology
Works count: 23
Citation count: 243
H-index: 5
I10-index: 3
Year
Topic
Type